Amplify Weight Loss Drug & Treatment ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Amplify Weight Loss Drug & Treatment ETF THNR
Morningstar’s Analysis THNR
Will THNR outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 65.6
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 11.45 | 657,265 | Healthcare |
Novo Nordisk AS ADR | 8.82 | 506,084 | Healthcare |
Amgen Inc | 6.14 | 352,457 | Healthcare |
Roche Holding AG Ordinary Shares new | 5.87 | 337,086 | Healthcare |
Pfizer Inc | 5.78 | 331,456 | Healthcare |
AbbVie Inc | 5.71 | 327,683 | Healthcare |
AstraZeneca PLC | 5.68 | 325,812 | Healthcare |
Gilead Sciences Inc | 5.54 | 318,153 | Healthcare |
Regeneron Pharmaceuticals Inc | 5.42 | 311,254 | Healthcare |
Merck & Co Inc | 5.20 | 298,161 | Healthcare |